Gastrointestinal Stromal Tumors (GISTs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Gastrointestinal Stromal Tumors (GISTs) Market Outlook Thelansis’s “Gastrointestinal Stromal Tumors (GISTs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastrointestinal Stromal Tumors (GISTs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Gastrointestinal Stromal Tumors (GISTs) Overview Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. Approximately 80% of GISTs harbor activating mutations in the KIT or PDGFRA genes that are responsible for the upregulation of crucial signaling pathways, including MAPK and PI3K-AKT. GISTs lackin...